Target intelligence / Profile preview

Human immunodeficiency virus type 1 glycoprotein 41 membrane-proximal external region (HIV-1 gp41 MPER)

Target
HIV-1 gp41 MPER
Molecular classification
Viral envelope protein, Transmembrane protein subunit, Fusion protein
01

Overview

The Human immunodeficiency virus type 1 (HIV-1) glycoprotein 41 (gp41) membrane-proximal external region (MPER) is a highly conserved, tryptophan-rich sequence located at the C-terminus of the gp41 ectodomain, adjacent to the viral transmembrane anchor (Sheng et al., 2014). It plays a pivotal role in the viral entry process by facilitating the fusion of the viral envelope with the host cell plasma membrane (Cardoso et al., 2005). Due to its critical function and low sequence variability across diverse HIV-1 clades, the MPER is a major target for broadly neutralizing antibodies (bNAbs) such as 4E10, 2F5, and 10E8 (Huang et al., 2012). These antibodies, particularly 4E10, recognize a linear epitope within the MPER and block the transition of gp41 into its fusogenic six-helix bundle conformation, thereby preventing infection (Sun et al., 2008). However, the MPER is partially occluded by the viral membrane and is only transiently exposed during the fusion process, making it a difficult target for vaccine-induced immunity (Haynes et al., 2005). Furthermore, some MPER-directed antibodies exhibit polyreactivity with host phospholipids, which poses potential safety concerns regarding autoimmunity and complicates the development of MPER-based therapeutics (Alam et al., 2009).

Other names
gp41 MPERMembrane-proximal external region of gp41HIV-1 envelope glycoprotein gp41 MPER4E10 epitope
02

Mechanism of action

Neutralization of viral entry by binding to the MPER and inhibiting the conformational changes of gp41 required for fusion of the viral and host cell membranes (Sun et al., 2008).

03

Biological functions

Viral entryMembrane fusionViral attachment
04

Disease associations

HIV-1 infectionAcquired immunodeficiency syndrome (AIDS)
05

Safety considerations

Viral escape mutationsAuto-reactivity with host lipids such as cardiolipin (Haynes et al., 2005)Low accessibility of the epitope during the fusion process
06

Interacting drugs

4E10 (investigational monoclonal antibody)

3 more in the full profile.

07

Biomarkers

HIV-1 viral loadCD4+ T-lymphocyte countAnti-gp41 antibody titers

Beyond the preview

Go deeper on Human immunodeficiency virus type 1 glycoprotein 41 membrane-proximal external region (HIV-1 gp41 MPER).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human immunodeficiency virus type 1 glycoprotein 41 membrane-proximal external region (HIV-1 gp41 MPER).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call